Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection

Anti-PSMA antibody radiolabeled with 177Lu improves MFS in high-risk nmCRPC

Erdafitinib demonstrates efficacy in intermediate-risk non–muscle-invasive bladder cancer with FGFR alterations

Cell-free utDNA may predict transurethral resection of bladder tumour pathology in non–muscle invasive bladder cancer

IMvigor130 study: Final OS analysis of atezo + plt/gem vs placebo + plt/gem used to treat mUC

Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer

JAVELIN Bladder 100: Avelumab maintenance indicated as a standard of care for advanced urothelial carcinoma

Stereotactic body radiotherapy compared with surgery for localised prostate cancer

Changes in planned disease management after PET/CT in men with biochemically recurrent prostate cancer and low PSA levels

Abiraterone acetate/prednisone + apalutimide and ADT with post-op SRT may improve PFS and MFS after prostatectomy

Safety and efficacy of immune checkpoint inhibitors in advanced penile squamous cell carcinoma

Choosing Wisely campaigns in Africa